產(chǎn)品描述: | VcMMAE (mc-vc-PAB-MMAE) is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc). |
靶點(diǎn): |
Auristatin;MicrotubuleAssociated |
體外研究: |
VcMMAE (MMAE) 在 CD30+ 癌細(xì)胞內(nèi)從 SGN-35 有效釋放,并且由于其膜滲透性,能夠?qū)ε杂^者細(xì)胞發(fā)揮細(xì)胞毒活性。MMAE 以與有絲分裂停滯相關(guān)的時(shí)間表和劑量依賴性方式使結(jié)直腸癌細(xì)胞和胰腺癌細(xì)胞對(duì) IR 敏感。放射增敏作用表現(xiàn)為受照射細(xì)胞中克隆形成存活率下降和 DNA 雙鏈斷裂增加 |
體內(nèi)研究: |
VcMMAE (MMAE) 與 IR 結(jié)合導(dǎo)致腫瘤生長(zhǎng)延遲,腫瘤靶向 ACPP-cRGD-MMAE 與 IR 在異種移植模型中產(chǎn)生更穩(wěn)健和顯著延長(zhǎng)的腫瘤消退 |
參考文獻(xiàn): |
1. Okeley, et al. Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate. Clinical Cancer Research (2010), 16(3), 888-897. 2. Lisa Buckel, et al. Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery. Cancer Res. 2015 Apr 1;75(7):1376-87. 3. Jianmin Fang, et al. Anti-her2 antibody and conjugate thereof. US 20160304621 A1. |
溶解性: |
soluble in DMSO |
保存條件: |
-20℃ |
配置溶液濃度參考: |
|
1mg |
5mg |
10mg |
1 mM |
0.76 ml |
3.798 ml |
7.595 ml |
5 mM |
0.152 ml |
0.76 ml |
1.519 ml |
10 mM |
0.076 ml |
0.38 ml |
0.76 ml |
50 mM |
0.015 ml |
0.076 ml |
0.152 ml |
|
注意: |
部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。 |